Clinical Policy: vilazodone (Viibryd®)
Reference Number: ERX.NSST.09
Effective Date: 06/15
Last Review Date: 09/16

Clinical policies are intended to be reflective of current scientific research and clinical thinking. This policy is current at the time of approval, may be updated and therefore is subject to change. This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

Description
The intent of the criteria is to ensure that patients follow selection elements established by Envolve Pharmacy Solutions for the use of vilazodone (Viibryd®).

Policy/Criteria
It is the policy of health plans affiliated with Envolve Pharmacy Solutions® that vilazodone (Viibryd®) is medically necessary for members meeting the following criteria:

Initial Approval Criteria (must meet all):
A. Age ≥ 18 years;
B. Failure of two selective serotonin reuptake inhibitors (SSRIs) or serotonin/norepinephrine reuptake inhibitors (SNRIs), each trialed for ≥ 30 days unless contraindicated;
C. Request does not exceed FDA approved maximum recommended dose and health plan approved daily quantity limit.

Approval duration: 12 months

Continued Approval (must meet all):
A. Previously received medication via health plan benefit or member has previously met all initial approval criteria;
B. If request is for a dose increase, request does not exceed FDA approved maximum recommended dose and health plan approved daily quantity limit.

Approval duration: 12 months
Workflow Document

USS.NSST.09
vilazodone (Viibryd)

Background
Description/Mechanism of Action
Vilazodone is a novel oral antidepressant that enhances serotonergic activity via a dual mechanism. Vilazodone has a high affinity for the serotonin reuptake site and 5-HT1A receptors. It does not exhibit a high binding affinity for norepinephrine or dopamine reuptake sites. Generally, the therapeutic effect of serotonin reuptake inhibitors is believed to occur via blockade of the reuptake of serotonin at the presynaptic neuronal membrane.

FDA Approved Indications
Viibryd is indicated for the treatment of major depressive disorder.

References

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy created.</td>
<td>06/15</td>
<td>06/15</td>
</tr>
<tr>
<td>Updated to new template (converted algorithm to bulleted criteria, added background and references).</td>
<td>07/16</td>
<td>09/16</td>
</tr>
</tbody>
</table>